ContextThe focus of thrombolytic therapy in acute stroke has been on favorable outcome at
3 months. Few studies have analyzed outcome at 24 hours. An early and reliable prediction …

Background: Thrombolytic therapy for acute ischemic stroke with IV alteplase is increasingly
well established in North America but not elsewhere. Baseline factors that altered the …

Background: Major neurologic improvement at 24 hours after administration of recombinant
tissue plasminogen activator (rt-PA) in acute stroke may predict good outcome at 3 months …

Background—Thrombolytic therapy with intravenous alteplase within 4.5 hours of ischemic
stroke onset increases the overall likelihood of an excellent outcome (no, or nondisabling …

Background and Purpose—We evaluated the clinical course of 19 acute stroke patients with
rapid early improvement of neurological deficit within the 3-hour window, treated with …

Background and Purpose—Although long-term outcome determinants in acute ischemic
stroke (AIS) patients have been defined, less is known about those predicting hyperacute …

BACKGROUND: We investigated a method for assessing early improvement and predictive
factors of early and late outcomes in patients receiving thrombolytic therapy. METHODS: A …

Background Studies have demonstrated that thrombolytic therapy for acute stroke can be
given safely and effectively in study settings with experienced clinicians, but the patient …

Background and Purpose—Intravenous thrombolysis with alteplase is approved for acute
ischemic stroke, but its use is limited by numerous contraindications and warnings arising …

Background Thrombolytic therapy for acute ischemic stroke with a lower-than-standard dose
of intravenous alteplase may improve recovery along with a reduced risk of intracerebral …